Vlad Coric, Biohaven CEO

Bio­haven’s pro­tein de­grad­er cuts an­ti­bod­ies by 60%

Bio­haven said the low­est dose of BHV-1300 cut the lev­els of the au­toim­mune an­ti­body IgG by more than 60%, ac­cord­ing to a new cut of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA